1-3 of 3
Bertrand Rabault
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluation of Deferasirox (Exjade®, ICL670) Therapy in Patients with Transfusional Iron Overload Who Achieve Serum Ferritin (SF) ≤1000 ng/mL in Long-Term Studies.

Maria Domenica Cappellini, Elliott Vichinsky, John M. Ford, Bertrand Rabault, John Porter
Journal: Blood
Blood (2007) 110 (11): 3795.
https://doi.org/10.1182/blood.V110.11.3795.3795
Published: 2007
Journal Articles

Semi-Quantitative Assessment of Hemosiderin Distribution Accurately Reflects Reductions in Liver Iron Concentration Following Therapy with Deferasirox (Exjade ® , ICL670) or Deferoxamine in Patients with Transfusion-Dependent Anemia.

Yves Deugnier, Bruno Turlin, Martine Ropert, Mohamed Bejaoui, Miranda Athanassiou-Metaxa, Holger Cario, Elliott Vichinsky, Herbert Opitz, Catherine Ressayre-Djaffer, Bertrand Rabault, John Ford
Journal: Blood
Blood (2005) 106 (11): 2708.
https://doi.org/10.1182/blood.V106.11.2708.2708
Published: 2005
Journal Articles

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

John Porter, MD, Elliot Vichinsky, MD, Christian Rose, MD, Antonio Piga, MD, Nancy Olivieri, MD, Norbert Gattermann, MD, Johan Maertens, MD, Bertrand Rabault, PhD, Insa Gathmann, MSc, Daniele Alberti, MD
Journal: Blood
Blood (2004) 104 (11): 3193.
https://doi.org/10.1182/blood.V104.11.3193.3193
Published: 2004